Technical Analysis for SLS - SELLAS Life Sciences Group, Inc.

Grade Last Price % Change Price Change
C 1.24 -3.88% -0.05
SLS closed down 3.88 percent on Wednesday, November 20, 2024, on 1.55 times normal volume. It was able to find support at its 50 day moving average. It was able to bounce off of its 200 day moving average, an important long-term support line.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
200 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Walk Strength -3.88%
Upper Bollinger Band Touch Strength -3.88%
Upper Bollinger Band Walk Strength -3.88%
Gapped Up Strength -3.88%
Upper Bollinger Band Touch Strength -3.88%
Upper Bollinger Band Walk Strength -6.06%

   Recent Intraday Alerts

Alert Time
Gap Up Closed about 16 hours ago
Gap Up Partially Closed about 16 hours ago
20 DMA Support about 16 hours ago
200 DMA Support about 16 hours ago
60 Minute Opening Range Breakdown about 16 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

SELLAS Life Sciences Group, Inc. Description

SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Solid Tumors Cancer Treatment Oncology Breast Cancer Acute Myeloid Leukemia Immunotherapies Antineoplastic Drugs Ovarian Cancer Treatment Of Breast Cancer Hematologic Malignancies Oncolytics Biotech Treatment Of Acute Myeloid Leukemia Novel Cancer Endometrial Cancer Pembrolizumab Gynaecological Cancer Gynaecology Ovarian And Endometrial Cancers

Is SLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.72
52 Week Low 0.4986
Average Volume 640,301
200-Day Moving Average 1.23
50-Day Moving Average 1.23
20-Day Moving Average 1.23
10-Day Moving Average 1.27
Average True Range 0.09
RSI (14) 50.25
ADX 20.36
+DI 16.87
-DI 14.71
Chandelier Exit (Long, 3 ATRs) 1.13
Chandelier Exit (Short, 3 ATRs) 1.33
Upper Bollinger Bands 1.35
Lower Bollinger Band 1.11
Percent B (%b) 0.56
BandWidth 19.53
MACD Line 0.02
MACD Signal Line 0.01
MACD Histogram 0.0074
Fundamentals Value
Market Cap 53.92 Million
Num Shares 43.5 Million
EPS -1.52
Price-to-Earnings (P/E) Ratio -0.82
Price-to-Sales 47.76
Price-to-Book 5.90
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.41
Resistance 3 (R3) 1.43 1.38 1.38
Resistance 2 (R2) 1.38 1.34 1.37 1.37
Resistance 1 (R1) 1.31 1.31 1.29 1.30 1.36
Pivot Point 1.27 1.27 1.25 1.26 1.27
Support 1 (S1) 1.19 1.22 1.17 1.18 1.12
Support 2 (S2) 1.15 1.19 1.14 1.11
Support 3 (S3) 1.08 1.15 1.10
Support 4 (S4) 1.07